secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059539
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01, 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Q1 net loss $32.2M; cuts 22% workforce; cash runway into H2 2025
-----------------------------------------------------------------------

- Net loss $32.2M ($0.40/share) vs $31.7M ($0.43) in Q1 2023; R&D spend $25.1M.
- Cash $122.2M at Mar 31; Feb follow-on raised $46.8M net; runway into H2 2025.
- Workforce reduced ~22% with $1.3-1.5M severance charges expected in Q2 2024.
- TN-201 initial Phase 1b data expected H2 2024; TN-401 RIDGE-1 sites activated.
- Hired Dr. Whedy Wang as SVP Biometrics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017024059539/0000950170-24-059539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017024059539/tnya-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer